解放军医学院学报Issue(11)：1103-1105,3.DOI:10.3969/j.issn.2095-5227.2015.11.012
直肠癌肝转移患者接受西妥昔单抗治疗后出现K-RAS基因突变的检测与治疗探讨
Detection and treatment of K-RAS gene mutation after administration of cetuximab in patients with metastatic colorectal cancer：A case report and literature review
摘要
Abstract
ObjectiveTo investigate the relationship between the emergence of KRAS mutations and the acquired resistance of metastatic colorectal cancer after treatment with cetuximab, and discuss the follow-up treatment strategy.Methods A retrospective analysis of clinical data about 1 patient (female, 70 years old) with K-RAS wild metastatic colorectal cancer after administration of cetuximab on November 15, 2014 in No.2 department of oncology in Chinese PLA General Hospital was performed and related literatures were reviewed.Results After administration of cetuximab for 43 months, the K-RAS gene mutations could be detected in the liver metastasis focus in the patient. Then, the patient was administrated with bevacizumab plus oxaliplatin. According to the RESICT Solid Tumors evaluation criteria, stable disease was observed in the patient. Conclusion The present study shows that early treatment with MEK inhibitors can significantly delay and reverse the resistance of cetuximab.关键词
转移性结直肠癌/K-RAS基因突变/西妥昔单抗Key words
metastatic colorectal cancer/K-RAS mutation/cetuximab分类
医药卫生引用本文复制引用
司海燕,王伟兰,戴广海..直肠癌肝转移患者接受西妥昔单抗治疗后出现K-RAS基因突变的检测与治疗探讨[J].解放军医学院学报,2015,(11):1103-1105,3.基金项目
吴阶平基金资助项目(320.6751.1201) Supported by by the Foundation of WU Jie-Ping(320.6751.1201) （320.6751.1201）
